Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BXRX

Baudax Bio (BXRX) Stock Price, News & Analysis

About Baudax Bio Stock (NASDAQ:BXRX)

Advanced Chart

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$3.47
Volume
310,872 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
See More Headlines

BXRX Stock Analysis - Frequently Asked Questions

Baudax Bio, Inc. (NASDAQ:BXRX) announced its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) EPS for the quarter, topping analysts' consensus estimates of ($2.04) by $0.55.

Shares of Baudax Bio reverse split on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/16/2023
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BXRX
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,790,000.00
Pretax Margin
-18,950.64%

Debt

Sales & Book Value

Annual Sales
$1.27 million
Price / Cash Flow
N/A
Book Value
($14.93) per share
Price / Book
0.00

Miscellaneous

Free Float
52,408,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
1.57
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BXRX) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners